Pharma swept up in biogenerics gold rush

Ratner, Mark
April 2009
Nature Biotechnology;Apr2009, Vol. 27 Issue 4, p299
Academic Journal
This article discusses the involvement of large pharmaceutical companies in the burgeoning field of biogenerics. Numerous drug corporations such as Merck BioVentures (MBV) and Pfizer have put up money to either bolster or acquire biotechnology companies such as Insmed and Wyeth. Biogenerics represent a potentially large market opportunity due to the fact that numerous patents on leading biologics are going to expire through 2017. MBV and GlycoFi are producing MK-2578, which is a PEGylated form of erythropoietin that was developed using the Pichia pastoris technology. No approval pathway exists for biogenerics in the U.S., so these products must receive preclinical toxicology screenings and phase 3 studies.


Related Articles

  • CHAPTER 92: LARGEST PHARMACEUTICAL COMPANIES. Miller, Richard K.; Washington, Kelli // Healthcare Business Market Research Handbook;2012, p385 

    A list of the top pharmaceutical corporations in terms of U.S. prescription sales in 2010 is presented including Pfizer, Merck & Co. and AstraZeneca.

  • Competitive Landscape.  // United States Pharmaceuticals & Healthcare Report;Q1 2010, p59 

    This article looks at the competitive landscape of the pharmaceutical industry in the U.S. It highlights the growth of U.S. pharmaceutical companies such as Pfizer, Merck & Co. and Abbott. It also observes industry consolidation and collaboration as a major trend through 2008 and 2009. In...

  • New generic launches buoy growth.  // Drug Store News;9/25/2006, Vol. 28 Issue 12, p26 

    The article reports on the expiration of patent licenses of major brand-name drugs which experts say the beginning of patent expirations of branded drugs spanning for 5 years in the U.S. Three of the major brand name drugs who lost its patent protection included Zocor manufactured by Merck...

  • Huge fight expected when statin patents expire. Moyer, Paula // Drug Topics;8/8/2005 Supplement, p24s 

    This article discusses the potential conflict over generic formulation plans for statin in the United States. A generic formulation for simvastatin has received temporary approval and others are expected to follow. However, major drug companies that manufacture statins, such as Pfizer Inc. and...

  • Drug giants can't shake flu.  // Dow Theory Forecasts;8/28/2006, Vol. 62 Issue 35, p1 

    The article reports on the business losses that big pharmaceutical companies, such as Pfizer Inc. and Merck & Co. Inc., are experiencing due to the emerging generic versions of their bestselling products. Studies have shown that new-drug approvals have decreased despite research and development...

  • US - Market Summary.  // U.S. Pharma & Healthcare Report;Q2 2009, p11 

    The article reports on the state of the pharmaceutical industry in the U.S., as of 2008. It is noted that the country has the highest per capita drug spending at $1,031. In 2008, the said industry had a value of $313.6 billion. Some of the biggest pharmaceutical companies based in the U.S. are...

  • Company Profiles.  // United States Pharmaceuticals & Healthcare Report;Q2 2012, Issue 2, p76 

    The article presents the profiles of leading pharmaceutical companies in the U.S. along with their strengths, weaknesses, opportunities and threats (SWOT) analysis and financial performance. These include Pfizer as the largest drugmaker in the world in terms of revenues, Merck & Co. as the top...

  • CLIFF NOTES. Iskowitz, Marc; Arnold, Matthew // Medical Marketing & Media;May2011, Vol. 46 Issue 5, p40 

    The article focuses on the performance of the pharmaceutical industry in the U.S. in 2010. It highlights the analysis from IMS Health Inc. which revealed an increase in the total sales of branded drugs by 2.3 percent to 307.3 billion dollars. According to Michael Kleinrock, director of research...

  • MarketLine Industry Profile: OTC Pharmaceuticals in the United States.  // OTC Pharmaceuticals Industry Profile: United States;9/1/2014, p1 

    The report presents a profile of the over the counter pharmaceuticals industry in the U.S., looking at companies including Merck & Co. Inc., Johnson & Johnson and Pfizer Inc. Topics include an executive summary of the industry as of September 2014, descriptions of the competitive landscape, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics